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Background: Neonatal hyperbilirubinemia, especially kernicterus, can be prevented by screening for neonatal
jaundice. The transcutaneous bilirubin (TcB) meter is a non-invasive medical device for screening neonates. The
study aimed to investigate the validity of a TcB meter in a resource-limited setting such as Mongolia.
Methods: Term and late preterm neonates from the National Center for Maternal and Child Health of Ulaanbaatar
in Mongolia who met the inclusion criteria (gestational age ≥35 weeks, birth weight ≥2000 g, postnatal age ≤ 1
month) were enrolled in the study. We used a TcB meter, JM-103 to screen for neonatal jaundice. TcB
measurements at the infant’s forehead and midsternum were performed within 3 h of obtaining samples for total
serum bilirubin (TSB) measurement. We analyzed the correlation between TcB measurements and TSB
measurements to validate the meter.
Results: A total of 47 term and six late preterm neonates were included in the study. TcB measured by the meter
at both the forehead and the midsternum showed a strong correlation with TSB measured in the laboratory. The
correlation equations were TSB = 1.409+0.8655 × TcB (R2=0.78871) at the forehead, and TSB = 0.7555+0.8974 × TcB
(R2=0.78488) at the midsternum. Bland-Altman plots and the Bradley-Blackwood test showed no significant
differences between the two methods at all measured ranges of bilirubin. The mean areas under the curves of TcB
at the forehead and midsternum at three TSB levels (>10 mg/dL, >13 mg/dL, >15 mg/dL) of TcB were greater than
0.9, and all had high sensitivity and specificity.
Conclusions: This study established the validity of the JM-103 meter as a screening tool for neonatal jaundice in
term and late preterm infants in Mongolia. Future studies are needed, including the establishment of a TcB hour-
specific nomogram, for more effective clinical practice to prevent severe hyperbilirubinemia.
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The guidelines of the American Academy of Pediatrics
(AAP) [1] indicate that transcutaneous bilirubin (TcB)
measurements are accurate in the diagnosis of neonatal
jaundice, and can reduce the need for blood sampling.
In addition, they recommend that all neonates undergo
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distribution, and reproduction in any mediumleast once before hospital discharge to assess their risk
of hyperbilirubinemia.
Severe hyperbilirubinemia (kernicterus and, irrevers-
ible neurological sequelae) in newborns is preventable
through appropriate follow-up, diagnosis, and treatment,
such as phototherapy and exchange transfusions [2-5].
Neonatal jaundice is more prevalent in the Asian popu-
lation [6], which may lead to a higher risk of developing
kernicterus. A study in Hong Kong reported that 23.9%
of Chinese newborns had a peak TSB>204 μmol/L (12
mg/dL) [7], whereas a study of Canada found that 6.7%
of newborns (predominantly white) had a peak TSBCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Clinical characteristics of the 53 ethnic
Mongolian neonates
Characteristics n (%)
Birth Weight (g): <2500 g 2 3.8
2500-3499 g 29 54.7
3500-4499 g 22 41.5
Gestational Age (week): 35-36 weeks 6 11.3
37-40 weeks 43 81.2
41-42 weeks 4 7.5
Delivery Mode: Normal Vaginal 41 77.4
Cesarean Section 12 22.6
Postnatal day of measurement of Day 0-10 19 35.9
Day 11-20 15 28.2
Day 21-31 19 35.9
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http://www.biomedcentral.com/1471-2431/13/151≥230 μmol/L (13.5 mg/dL) [8]. Setia et al. [9] reported
that the risk of severe jaundice, requiring phototherapy,
blood transfusion, or rehospitalization, was significantly
elevated in infants of full East Asian parentage.
The second generation transcutaneous jaundice meter
(JM-103, Konica Minolta, Osaka, Japan) is a non-invasive
medical device that is easy to use at the bedside, delivers
prompt measurements, and is minimally influenced by
skin pigmentation. According to the manufacturer’s in-
structions, it can be used for infants up to 1 month of age.
Yasuda et al. [10] found an excellent correlation (r=0.93)
between TcB (measured by JM-103) and TSB among Japa-
nese term neonates. This diagnostic test was further vali-
dated among several ethnic groups in North America
[11,12], Europe [13], and Asia [14,15].
Neonatal hyperbilirubinemia, especially kernicterus,
could be prevented in a resource-limited setting where
phototherapy is available by screening for neonatal jaun-
dice. In Mongolia, phototherapy is available at secondary
care hospitals. If the doctors in the primary care clinics
can identify neonatal jaundice and refer the neonates to
the secondary care hospital promptly, the neonates can
be treated with phototherapy. However, a TcB test as
screening tool for neonatal jaundice has not yet been
validated in Mongolia.
To investigate the validity of the TcB meter in a resource-
limited setting, we compared bilirubin levels measured by




We collected data on newborns (gestational age≥35
weeks, birth weight ≥2000 g, postnatal age ≤ 1 month)
who were admitted to the Neonatal Pathological Unit in
the National Center for Maternal and Child Health
(NCMCH) of Ulaanbaatar in Mongolia between October
1, 2010 and January 31, 2011. NCMCH is one of the ter-
tiary hospitals for children in Mongolia.
This study was approved by the NCMCH ethics
committee in Mongolia and the National Center for
Global Health and Medicine (NCGM) human investiga-
tion ethics committee in Japan. Oral informed consent
was obtained from the patients’ parents or guardians
and approved by each ethics committee.
Measurements
Measurement of TSB levels was based on the clinical indi-
cations (e.g., jaundice, or poor feeding). Blood was
obtained by venipuncture, and collecting tubes were
shielded from exposure to light. TSB levels were measured
by a photometric analyzer (DiaSys Diagnostic Systems,
Holzheim, Germany) in the hospital clinical chemistry la-
boratories. TcB levels were obtained within 3 h ofsampling for TSB measurement through the use of the
transcutaneous jaundice meter, JM-103 (Konica Minolta,
Osaka, Japan), by designated pediatricians. Of the three
most commonly used TcB meters (JM-103, Bilicheck and
BiliMed), JM-103 and Bilicheck (SpectRX, Norcross, GA,
USA) have been found to be the most reliable screening
tools for hyperbilirubinemia [16]. The principles of operat-
ing the JM-103 and its measurement techniques have been
described previously [10]. Briefly, TcB was measured at
both the forehead (uncovered) and the midsternum (cov-
ered) three times each, and the median value was desig-
nated as the TcB at each measurement site.
Statistical analysis
Linear regression analysis was used to determine the asso-
ciation between the two methods of measurement. We
used Bland-Altman plots [17] (mean and 95% confidence
intervals [CI]) to determine whether the difference
obtained between the two methods was stable at all mea-
sured ranges of bilirubin, and the equality of the mean
values and variances was examined using the Bradley-
Blackwood test [18]. The Bradley-Blackwood test is a
measure of agreement and simultaneously tests the
equivalence of means and variances of two paired mea-
surements. Pearson correlation coefficients (r) and coeffi-
cient of determination (R2) were calculated for TSB and
TcB at both sites. We also constructed receiver operating
characteristics (ROC) curves [19] for JM-103 cutoff values
(mg/dL) at TSB >10 mg/dL, >13 mg/dL, and >15 mg/dL.
All data were analyzed using JMP statistical software ver-
sion 9.0.2 (SAS Institute, Cary, NC, USA).
Results
The study population consisted of 53 ethnic Mongolian
neonates. The clinical characteristics (gestational age,
birth weight, delivery mode, and postnatal day of mea-
surement of TSB and TcB) of the study population are
Table 2 Summary statistics of bilirubin measurements
Variable N Mean 95% CI SD Minimum Q1 Median Q3 Maximum
TSB 53 12.55 1.70-21.01 4.819 1.7 9.20 12.5 15.95 21.6
TcB Forehead 53 12.87 1.07-21.56 4.945 1.0 9.75 12.9 16.25 21.7
TcB Midsternum 53 13.12 1.72-21.63 4.755 1.4 9.85 13.7 16.00 21.8
TSB: total serum bilirubin; TcB: transcutaneous serum bilirubin; SD: standard deviation; CI: confidence interval.
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TSB and TcB was distributed fairly evenly over a 1-
month period postnatally.
Table 2 summarizes mean (95% CI) levels of TSB and
TcB (forehead and midsternum) and shows similarities be-
tween all three measurements. Linear regression analysis
and Bland-Altman plots (mean and 95% CI) are shown in
Figures 1 and 2. The Pearson correlation coefficients with
respect to TSB were as follows: TcB forehead, 0.888
(R2=0.78871); and TcB midsternum 0.886 (R2=0.78488).
The equality of the mean values and variances according
to the Bradley-Blackwood test for all measured ranges
of bilirubin are shown in Figure 2. The P-value for the
comparison between TSB and TcB (forehead) was 0.315
(Figure 2A), for the comparison between TSB and TcB
(midsternum) was 0.073 (Figure 2B), and for the compari-
son between TcB (forehead) and TcB (midsternum) was
0.247 (Figure 2C).Figure 1 Linear regression plots (solid lines) of JM-103 TcB versus TSB
B: midsternum) in the neonate.The ROC curves of mean TcB at TSB >10 mg/dL,
TSB >13 mg/dL, and TSB >15 mg/dL are shown in
Figure 3, and demonstrate graphically the acceptable
specificity and sensitivity of mean TcB measurements at
these threshold levels of TSB. All sites and levels
showed the discriminatory power of the test. The areas
under the curve (AUC) of forehead TcB levels were
0.961 at TSB >10 mg/dL, 0.945 at TSB >13 mg/dL, and
0.907 at TSB >15 mg/dL (Figure 3A, B, C). The AUC
of midsternum TcB were 0.987 at TSB >10 mg/dL,
0.913 at TSB >10 mg/dL, and 0.902 at TSB >15 mg/dL
(Figure 3D, E, F).
Discussion
This study demonstrated a strong correlation between
TcB and TSB measured at both the forehead and
midsternum of ethnic Mongolian neonates. Since Yasuda
et al. [10] published the accuracy of TcB measurementmeasurements at different measurement sites (A: forehead,
Figure 2 Bland-Altman plots of TSB and TcB in the neonates. The graphs show the difference in mean values between TSB and TcB
(forehead) (A), TSB and TcB (midsternum) (B), and TcB (midsternum) and TcB (forehead) (C). The P-value by the Bradley-Blackwood test was 0.315
in (A), 0.073 in (B) and 0.247 in (C). FH: forehead; CH: midsternum.
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studies have been performed [11-16]. Regarding other
Asian populations, a strong correlation between TcB and
TSB was reported in a study in Thailand [14]. However,
a study in Chinese newborns suggested that there was a
significant difference between TcB and TSB [15]. In a
previous study in an African American population, there
was a lower correlation between the two measurements
[11], but other populations, such as Caucasians andEuropeans, showed a strong correlation [12,13,16]. The
accuracy of TcB in our study was similar to that in some
validated populations. A multi-ethnic population in the
United States showed TcB AUC of 0.962 at 10 mg/dL
TSB, 0.963 at 13 mg/dL, and 0.975 at 15 mg/dL [11], an
Israeli population showed AUC of 0.958 at TSB 10 mg/
dL, 0.971 at 13 mg/dL and 0.976 at 15 mg/dL, [13], and
a Thai population showed AUC of 0.851 at TSB 10 mg/
dL, 0.830 at 13 mg/dL, 0.958 at 15 mg/dL [14]. The
Figure 3 Receiver operating characteristics curves for JM-103 cutoff values (mg/dL) at TSB >10 mg/dL, >13 mg/dL, or >15 mg/dL.
The areas under the curves were 0.962 (A), 0.945 (B), 0.908 (C), 0.987 (D), 0.913 (E), and 0.903 (F).
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specificity of 89.4% and 100%, respectively, at TSB 10
mg/dL, of 93.6% and 90.5%, respectively, at 13 mg/dL,
and 100% each at 15 mg/dL [13]. In the Thai population,
sensitivity and specificity were 89.4% and 37.5%, respect-
ively, at TSB 10 mg/dl, 93.6% and 65.7%, respectively, at
13 mg/dL, and 100% and 85.4%, respectively, at 15
mg/dL [14]. Our results validate the use of TcB as an al-
ternative, quick and convenient measure of TSB in eth-
nic Mongolian neonates.
There are a number of previous reports of the com-
parison between TcB and TSB, with variability in study
design. All hospital-based studies used convenience sam-
ples, but there were large variations in the number of in-
fants (minimum 77 [10] and maximum 997 [15]). There
were differences in inclusion criteria (e.g., healthy term
or late preterm infants), in exclusion criteria (e.g., gesta-
tional age less than 35 weeks, receiving phototherapy,
ABO incompatibility, Rh incompatibility, major congeni-
tal malformation, hemoglobinopathies or evidence of
liver disease), in the TcB measurement site (e.g., fore-
head, midsternum, or both sites), in the number ofmeasurements (1 to 5 times), and in ethnicity. Studies
have been performed in Asian populations in Japan [10],
Thailand [14], and China [15], and in mixed race coun-
tries such as the United States (white, African-American,
East Asian, and Middle eastern) [11], Canada (Caucasian
and Non-Caucasian) [12], Israel (Ashkenazi, Sephardic,
and Ethiopian) [13], and Italy (Caucasian and West
African) [16]. In addition, TSB was measured by different
methods (e.g., photometric, colorimetric, direct spec-
trophotometry, and high performance liquid chromatog-
raphy). Because of these variations, there were no
comprehensive studies. Therefore, it was worthwhile to
perform this validation study in a resource-limited setting
like Mongolia. However, the limitations of our study were
that i) the sample size was relatively small compared with
previous studies; ii) the analyzed infants had medical indi-
cations for admission to a single hospital; and iii) the in-
fants were relatively older than in previous reports. In
addition, the Bradley-Blackwood test for all measured
ranges of bilirubin did not clearly present equivalence, be-
cause our sample size was relatively small and had low
statistical power.
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and late preterm neonates who required re-admittance
for visible jaundice and other medical reasons after dis-
charge. We were allowed to take their blood samples, in-
cluding TSB, for diagnosis and management. The 3-h
time difference between sampling for TSB measurement
and TcB measurement was relatively long compared
with previous studies. However, this longer time period
may not affect the differences between TSB and TcB. In
most cases (n=45, 84.9%), we performed the measure-
ments at postnatal 6 day or later (Table 1). TSB tends to
increase on an hourly basis until day 4 or 5 after birth,
then plateaus and decreases gradually [1].
Because the AAP recommends that TcB measurements
are accurate and constitute a viable alternative to TSB that
can reduce the need for blood sampling, a TcB hour-
specific nomogram has been constructed in many coun-
tries [20-26]. DeLuca et al. [27] observed that TcB levels
plateau and then decrease after 96 h of life in healthy neo-
nates, with some differences across populations. Thus, it is
necessary to create a Mongolian ethnicity-specific TcB
nomogram in the near future.
The JM-103 meter had good validity. This tool is
non-invasive and easy to use, gives prompt measure-
ments, and is minimally influenced by skin pigmenta-
tion. Thus, it might afford the possibility of screening
jaundice in a home visit setting. The TcB jaundice
meter would be suitable for the early detection of
subsequent hyperbilirubinemia. Therefore, we would
need to create a TcB hour-specific nomogram to pre-
vent severe hyperbilirubinemia in Mongolia.
Conclusion
This study established the validity of the JM-103 meter
as a screening tool for neonatal jaundice in term and
late preterm Mongolian infants. However, future stud-
ies are needed to create a TcB hour-specific nomogram
for more effective clinical practice to prevent severe
hyperbilirubinemia.
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